IONS
Ionis Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$52.95-2.65%
Price as of Jul 20, 2026
IONS financials
Ionis Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $944.0M | $705.1M | $787.6M | $587.4M |
| Cost of revenue | $16.0M | $11.2M | $9.1M | $14.1M |
| Gross profit | $928.0M | $693.9M | $778.5M | $573.3M |
| Operating expenses | $1.3B | $1.2B | $1.1B | $983.4M |
| Operating income | -$382.0M | -$475.1M | -$353.7M | -$410.2M |
| Net income | -$381.0M | -$453.9M | -$366.3M | -$269.7M |
| EBITDA | -$286.7M | -$353.7M | -$235.9M | -$227.8M |
| Basic EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 |
| Diluted EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 |
| Balance sheet | ||||
| Cash & equivalents | $372.3M | $242.1M | $399.3M | $276.5M |
| Total assets | $3.5B | $3.0B | $3.0B | $2.5B |
| Total liabilities | $3.0B | $2.4B | $2.6B | $2.0B |
| Stockholders’ equity | $489.1M | $588.4M | $386.7M | $572.9M |
| Total debt | $2.6B | $1.4B | $1.5B | $1.4B |
| Net debt | $2.2B | $1.2B | $1.1B | $1.1B |
| Cash flow | ||||
| Operating cash flow | -$268.6M | -$500.9M | -$307.5M | -$274.4M |
| Capital expenditure | -$51.4M | -$45.3M | -$28.0M | -$20.1M |
| Free cash flow | -$320.0M | -$546.2M | -$335.5M | -$294.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |